Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Post Q1 2025 Earnings of $3.52 Per Share, Zacks Research Forecasts

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Zacks Research raised their Q1 2025 earnings estimates for shares of Vertex Pharmaceuticals in a note issued to investors on Wednesday, April 3rd. Zacks Research analyst R. Department now expects that the pharmaceutical company will post earnings of $3.52 per share for the quarter, up from their previous forecast of $3.48. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $14.95 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.82 EPS, FY2025 earnings at $14.81 EPS and Q1 2026 earnings at $3.75 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the company posted $3.33 earnings per share.

A number of other research firms have also recently weighed in on VRTX. Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 2nd. Canaccord Genuity Group reaffirmed a “sell” rating and set a $379.00 target price (up previously from $332.00) on shares of Vertex Pharmaceuticals in a report on Wednesday, January 24th. Evercore ISI lowered shares of Vertex Pharmaceuticals from an “outperform” rating to an “in-line” rating and upped their price target for the company from $436.00 to $438.00 in a research note on Tuesday, February 6th. Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, StockNews.com downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 30th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $420.48.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $404.48 on Monday. Vertex Pharmaceuticals has a 12-month low of $316.43 and a 12-month high of $448.40. The firm has a market capitalization of $104.54 billion, a price-to-earnings ratio of 29.12, a P/E/G ratio of 2.21 and a beta of 0.35. The stock’s 50 day moving average price is $418.30 and its two-hundred day moving average price is $395.14. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CAO Kristen Ambrose sold 1,374 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $577,409.76. Following the sale, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at $4,066,242.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Kristen Ambrose sold 1,374 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $577,409.76. Following the completion of the sale, the chief accounting officer now directly owns 9,676 shares of the company’s stock, valued at $4,066,242.24. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock worth $5,203,249 over the last ninety days. 0.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. LSV Asset Management lifted its stake in shares of Vertex Pharmaceuticals by 206.3% in the first quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock valued at $1,240,000 after buying an additional 3,200 shares in the last quarter. Synovus Financial Corp lifted its position in Vertex Pharmaceuticals by 9.6% in the 1st quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock valued at $1,759,000 after acquiring an additional 590 shares in the last quarter. Cibc World Market Inc. boosted its stake in Vertex Pharmaceuticals by 69.4% during the 1st quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock valued at $1,728,000 after purchasing an additional 2,713 shares during the last quarter. Sei Investments Co. increased its holdings in Vertex Pharmaceuticals by 28.4% during the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock worth $11,756,000 after purchasing an additional 9,761 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Vertex Pharmaceuticals by 4.0% in the first quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after purchasing an additional 544 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.